Top section
Top section
I thought the grass would be greener in fintech land, but it’s patchy and dreary
Hybrid capital is open to the big US tech companies. But who needs an umbrella when the sun is shining?
Years of underperformance are behind it and the bank has launched a new growth plan
More articles
More articles
More articles
-
Clean, green energy exists; it is more or less unlimited and it is increasingly cheap to harvest through solar and wind farms. Why are we not converting to renewables wholesale — especially in poor countries, which tend to have abundant sunshine? A significant part of this market failure is financial, and capital markets must solve it. -
The Covid-19 crisis, and particularly the equity rally since the bottom of the sell-off in March, should cause deep reflection for active fund managers at risk of underperforming if they stick to their principles.
-
Healthy financial systems should not rely on short sellers and journalists to expose accounting scandals at large, publicly listed companies. Regulators and auditors should have been the heroes of the Wirecard story but their inability to see what others saw plainly paints them as the villains in this edition of German corporate noir.
-
Banks are hoping that there will be more European primary capital raising in the weeks ahead as companies begin to assess what will be needed to rebuild their balance sheets and whether the time is ripe for growth. A €341m share trade in German firm CompuGroup Medical on Monday night may show a way forward for issuers.
-
Zhen Ding Technology Holding tapped the equity-linked market on Monday with a zero coupon convertible bond.
-
German pharmaceuticals company Boehringer Ingelheim has sold its remaining stake in UK drug maker Hikma Pharmaceuticals, after a surge in investor interest in pharma stocks during the Covid-19 global pandemic.
Sub-sections
shared comment list
